Sponsor or institution
Clinical trials and research at Guangzhou Lupeng Pharmaceutical Company LTD.
As of November 12, 2026, Find a Trial lists 9 clinical trials run by Guangzhou Lupeng Pharmaceutical Company LTD. that are recruiting, in China. By phase: Phase 1 (4), Phase 2 (3), Phase 1/2 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 9Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Rocbrutinib in PRL-Positive Relapsing-Remitting MS | Phase 2 | Beijing, Beijing Municipality | Recruiting | Aug 20, 2026 |
| Rocbrutinib and Lacutoclax in B-cell cancers | Phase 1/2 | Tianjin | Recruiting | May 27, 2026 |
| Lacutoclax for Relapsed or Refractory CLL/SLL | Phase 2 | Nanjing, Jiangsu | Recruiting | May 27, 2026 |
| Rocbrutinib plus R-GemOx for relapsed/refractory DLBCL | Phase 1 | Guangzhou, Guangdong and 1 other locations | Recruiting | May 6, 2026 |
| Rocbrutinib versus other BTK inhibitors for relapsed or refractory mantle cell lymphoma | Phase 3 | Beijing, Beijing Municipality and 1 other locations | Recruiting | Jan 30, 2026 |
| Effects of itraconazole or rifampin on rocbrutinib levels in healthy adults. | Phase 1 | Beijing, Beijing Municipality | Recruiting | Jan 28, 2026 |
| Rocbrutinib for adults with relapsed or refractory non‑GCB diffuse large B‑cell lymphoma | Phase 2 | Hefei, Anhui and 40 other locations | Recruiting | Sep 23, 2025 |
| Assessing the safety and effectiveness of LP-108 with azacitidine for blood cancers | Phase 1 | Nanchang and 2 other locations | Recruiting | Dec 7, 2022 |
| Testing LP-168 for patients with B-cell lymphoma that hasn't responded to previous treatments | Phase 1 | Beijing, Beijing Municipality and 2 other locations | Recruiting | Aug 6, 2021 |
All recruiting trials (9)
-
Rocbrutinib in PRL-Positive Relapsing-Remitting MS
This study tests whether Rocbrutinib can help people with relapsing-remitting MS who have paramagnetic rim lesions, compared to dimethyl fumarate.
-
Rocbrutinib and Lacutoclax in B-cell cancers
This study tests whether Rocbrutinib plus Lacutoclax can help adults with B-cell malignancies, including CLL/SLL, MCL, DLBCL, FL, WM, who have had prior therapy or are treatment-naïve under specific criteria.
-
Lacutoclax for Relapsed or Refractory CLL/SLL
A pill called Lacutoclax is being tested to see if it helps adults with CLL/SLL whose disease has come back or not responded to prior treatment.
-
Rocbrutinib plus R-GemOx for relapsed/refractory DLBCL
This early-stage study tests whether combining Rocbrutinib with R-GemOx is safe and shows promise in people with relapsed or refractory non-GCB DLBCL.
-
Rocbrutinib versus other BTK inhibitors for relapsed or refractory mantle cell lymphoma
This trial tests whether rocbrutinib works better than other BTK inhibitors for people with mantle cell lymphoma that returned or didn't respond after at least one prior treatment and who have not previously received a BTK inhibitor (except for intolerance).
-
Effects of itraconazole or rifampin on rocbrutinib levels in healthy adults.
This test will see if the antifungal itraconazole or the antibiotic rifampin change how rocbrutinib is absorbed, distributed, and cleared in healthy adults.
-
Rocbrutinib for adults with relapsed or refractory non‑GCB diffuse large B‑cell lymphoma
This test tries rocbritinib alone versus the doctor's choice of bendamustine‑rituximab or lenalidomide‑rituximab in adults whose non‑GCB diffuse large B‑cell lymphoma has relapsed or not responded after at least two prior treatments.
-
Assessing the safety and effectiveness of LP-108 with azacitidine for blood cancers
This study is testing a new combination of LP-108 and azacitidine to see if it helps people with blood cancers like acute myeloid leukemia, myelodysplastic syndromes, or chronic myelomonocytic leukemia feel better and stay safe during treatment.
-
Testing LP-168 for patients with B-cell lymphoma that hasn't responded to previous treatments
This study is testing a new oral medication called LP-168 to see if it can help patients with B-cell lymphoma who haven't had success with other treatments.
Quick answers
How many clinical trials run by Guangzhou Lupeng Pharmaceutical Company LTD. are recruiting right now?
9, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 4, Phase 2: 3, Phase 1/2: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.